Nxera Pharma Co., Ltd.
4565・Prime Market・Pharmaceuticals
Governance
The company is a company with a Nomination Committee, etc. Of the 7 directors, 6 are outside directors (outside director ratio of approximately 86%), and the company has established three committees: Nomination, Compensation, and Audit. Management oversight and business execution are clearly separated, with business execution authority delegated to 3 executive officers.
Risk Management
The Board of Directors has resolved the basic policy for the internal control system, and the Internal Audit Department conducts internal audits in close collaboration with the Audit Committee. A framework has been established to identify and prioritize risks across the group as a whole, and to respond appropriately with reference to the opinions of external experts as needed.
Shareholder Returns
Continuing a no-dividend policy. Annual dividends are ¥0 for both FY2025 (ending December 2025) and FY2026 (ending December 2026). Priority is given to active business investment, and no dividend implementation is planned in the near future. A minimal amount of treasury stock repurchase was conducted during the current quarter (1,981 shares held).
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0 (¥0 at second quarter-end, ¥0 at year-end). The forecast for FY2026 (ending December 2026) is also an annual dividend of ¥0 (¥0 at second quarter-end, ¥0 at year-end). The policy is to determine dividends taking into account business performance, financial condition, cash needs, future outlook, distributable profits, and other factors; however, priority is currently given to active business investment, and no implementation of dividends from surplus or similar measures is planned in the near future.
ESG
Conducted climate change scenario analysis (RCP2.6 and RCP8.5) based on TCFD recommendations, and assessed the current business impact as limited. Scope 1+2 GHG emissions for FY2024 were 1,001.64 t-CO2. In terms of human capital, the company achieved a 59% ratio of foreign national employees and a 30% ratio of female managers, and has established DEI promotion, pay equity, and equity compensation schemes such as RSUs and J-ESOP. Materiality issues and KPIs were approved by the Board of Directors in March 2023.
Last updated: March 25, 2026